Contineum Therapeutics Net Income

Contineum Therapeutics (CTNM) currently reports a net income of $-58M as of June 2026. That compares with $-57M in the prior-year period — down 1.2% year over year. That is below the sector sector average of $98M. Use the charts on this page to explore Contineum Therapeutics's net income history and peer comparisons.

Contineum Therapeutics's net income decreased from $-57M to $-58M — a 1.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Contineum Therapeutics's net income of $-58M is lower than the its sector sector average of $98M. That is roughly 158.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Contineum Therapeutics reported $-58M in net income as of June 2026. That compares with $-57M in the prior-year period — down 1.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-58M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $98M. From there, open related valuation or income-statement pages for Contineum Therapeutics, and consider following CTNM for alerts when major investors trade the stock.